Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Squarepoint Ops LLC

Squarepoint Ops LLC reduced its holdings in shares of Xencor, Inc. (NASDAQ:XNCR) by 45.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,291 shares of the biopharmaceutical company’s stock after selling 11,204 shares during the period. Squarepoint Ops LLC’s holdings in Xencor were worth $305,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in XNCR. RTW Investments LP increased its holdings in shares of Xencor by 317.9% during the fourth quarter. RTW Investments LP now owns 2,402,883 shares of the biopharmaceutical company’s stock valued at $55,218,000 after acquiring an additional 1,827,883 shares in the last quarter. BVF Inc. IL increased its holdings in shares of Xencor by 169.3% during the fourth quarter. BVF Inc. IL now owns 2,288,760 shares of the biopharmaceutical company’s stock valued at $52,596,000 after acquiring an additional 1,438,760 shares in the last quarter. Nuveen Asset Management LLC increased its stake in Xencor by 452.4% during the 4th quarter. Nuveen Asset Management LLC now owns 837,082 shares of the biopharmaceutical company’s stock valued at $19,236,000 after purchasing an additional 685,557 shares in the last quarter. Finepoint Capital LP acquired a new position in Xencor during the 4th quarter valued at approximately $15,167,000. Finally, Vanguard Group Inc. increased its stake in Xencor by 5.5% during the 4th quarter. Vanguard Group Inc. now owns 8,017,366 shares of the biopharmaceutical company’s stock valued at $184,239,000 after purchasing an additional 418,040 shares in the last quarter.

Xencor Stock Up 5.8%

XNCR stock opened at $9.65 on Friday. The firm has a market cap of $686.80 million, a PE ratio of -3.02 and a beta of 0.99. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. The firm’s fifty day moving average is $8.98 and its 200 day moving average is $15.71. Xencor, Inc. has a one year low of $7.16 and a one year high of $27.24.

Xencor (NASDAQ:XNCR) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.06). Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business had revenue of $32.73 million for the quarter, compared to analyst estimates of $23.44 million. During the same quarter last year, the business earned ($1.11) earnings per share. Xencor’s revenue was up 104.6% on a year-over-year basis. On average, research analysts forecast that Xencor, Inc. will post -3.68 EPS for the current year.

Insider Buying and Selling at Xencor

In related news, EVP Nancy Valente sold 4,616 shares of Xencor stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $11.03, for a total value of $50,914.48. Following the sale, the executive vice president now owns 49,169 shares of the company’s stock, valued at approximately $542,334.07. This trade represents a 8.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.76% of the stock is owned by corporate insiders.

Analyst Ratings Changes

XNCR has been the topic of several research reports. Barclays cut their target price on Xencor from $22.00 to $6.00 and set an “underweight” rating on the stock in a research report on Thursday, May 8th. William Blair began coverage on Xencor in a report on Monday, April 21st. They issued an “outperform” rating on the stock. Wall Street Zen downgraded shares of Xencor from a “hold” rating to a “sell” rating in a report on Friday, March 14th. Wedbush reiterated an “outperform” rating and issued a $31.00 price objective on shares of Xencor in a research note on Wednesday, April 30th. Finally, Wells Fargo & Company cut their price objective on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $29.50.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.